Recombinant Rat IL-17E Protein, CF

• Reactivity: Rt
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Rat IL-17E Protein, CF Summary

• Details of Functionality: Measured by its ability to induce CXCL1/GRO alpha secretion in HT‑29 human colon adenocarcinoma cells. The ED₅₀ for this effect is 0.25-1.25 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived rat IL-17E/IL-25 protein
  Val17-Ala169
• Accession #: D3ZLB1
• N-terminal Sequence: Val17
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: Il25
• Purity: >80%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 18 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 19-25 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in HCl with Trehalose.
• Purity: >80%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in 4 mM HCl.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Rat IL-17E Protein, CF

• IL17E
• IL-17E
• IL25
• IL-25
• interleukin 25
• Interleukin-17E
• interleukin-25

Background

The Interleukin-17 (IL-17) family of proteins are immunoregulatory cytokines that share a conserved cysteine-rich region. IL-17E, which is also known as IL-25, promotes Th2-biased immune responses. This is in contrast to other IL-17 family members which promote Th1- and Th17-biased inflammation. IL-25 is an important mediator of allergic reactions and protection against intestinal parasites (1, 2). Mature rat IL-25 shares 80% and 91% amino acid sequence identity with mouse and human IL-25, respectively (3, 4). During helminth infections and allergic reactions, IL-25 is locally up-regulated in intestinal and airway epithelial cells, atopic dermatitis skin lesions, and local Th2 cells, eosinophils, and basophils (4-9). It binds to IL-17 RB but also requires IL-17 RA to exert its activity (3, 8, 10). IL-25 acts on a variety of cell types which respond with increased production of Th2 cytokines (e.g. IL-4, IL-5, IL-13) and reduced production of Th1 and Th17 cytokines (e.g. IFN-gamma , IL-12, IL-23, IL-17A, IL-17F) (4-6, 8, 9, 11-15). Airway IL-25 can be activated by MMP-7, a protease that is up-regulated in airway epithelium in response to allergen exposure (16). Cleaved IL-25 shows enhanced binding to IL-17 RB and stronger induction of Th2 cytokines (16). The Th2 cytokines, in turn, trigger expansion of Th2 memory cells and anti-inflammatory M2 macrophages, increased eosinophil mobilization and activation, and dendritic cell migration (4, 6, 9, 13). These actions promote protective anti-helminth immune responses (4, 5) as well as allergic inflammation and airway hyperreactivity (11). The IL-25 induced suppression of Th1 and Th17 cytokines limits Th17 cell expansion and disease pathology in autoimmunity and colitis (12, 15). IL-25 also promotes vascular endothelial cell proliferation and assembly into tubular structures (7). It supports the integrity of the blood-brain barrier and limits CD4+ T cell infiltration into the brain (17).

1. Saadoun, D. et al. (2011) Curr. Pharm. Des. 17:3781.
2. Iwakura, Y. et al. (2011) Immunity 34:149.
3. Lee, J. et al. (2001) J. Biol. Chem. 276:1660.
4. Fort, M.M. et al. (2001) Immunity 15:985.
5. Zhao, A. et al. (2010) J. Immunol. 185:6921.
6. Suzukawa, M. et al. (2012) J. Immunol. 189:3641.
7. Corrigan, C.J. et al. (2011) Proc. Natl. Acad. Sci. USA 108:1579.
8. Petersen, B.C. et al. (2012) Nat. Med. 18:751.
9. Wang, Y.-H. et al. (2007) J. Exp. Med. 204:1837.
10. Rickel, E.A. et al. (2008) J. Immunol. 181:4299.
11. Hurst, S.D. et al. (2002) J. Immunol. 169:443.
12. Kleinschek, M.A. et al. (2007) J. Exp. Med. 204:161.
13. Cao, Q. et al. (2011) J. Am. Soc. Nephrol. 22:1229.
14. Stock, P. et al. (2009) J. Immunol. 182:5116.
15. Caruso, R. et al. (2009) Gastroenterology 136:2270.
16. Goswami, S. et al. (2009) Nat. Immunol. 10:496.
17. Sonobe, Y. et al. (2009) J. Biol. Chem. 284:31834.

Publications for IL-17E/IL-25 (8949-IL/CF)(1)

Publication using 8949-IL/CF

• CY Chang, J Wang, Y Zhao, J Liu, X Yang, X Yue, H Wang, F Zhou, JM Inclan-Ric, JJ Ponessa, P Xie, L Zhang, MC Siracusa, Z Feng, W Hu Tumor suppressor p53 regulates intestinal type 2 immunity Nature Communications, 2021-06-07;12(1):3371. 2021-06-07 [PMID: 34099671] (In Vivo, Mouse)

Bioinformatics

• Gene Symbol: Il25
• Uniprot:
  • D3ZLB1()